About profound medical corp - PROF
Profound Medical Corp. is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the ablation of diseased tissue utilizing its platform technologies. The firm’s product, the TULSA-PRO system, combines real-time MRI, robotically driven transurethral sweeping action/thermal ultrasound, and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It is also focused on developing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. The company was founded on June 13, 2008 and is headquartered in Mississauga, Canada.
PROF At a Glance
Profound Medical Corp.
2400 Skymark Avenue
Mississauga, Ontario L4W 5K5
| Phone | 1-647-476-1350 | Revenue | 16.10M | |
| Industry | Medical Specialties | Net Income | -42,570,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 50.73% | |
| Fiscal Year-end | 12 / 2026 | Employees | 162 | |
| View SEC Filings |
PROF Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 14.756 |
| Price to Book Ratio | 4.292 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -4.485 |
| Enterprise Value to Sales | 11.339 |
| Total Debt to Enterprise Value | 0.026 |
PROF Efficiency
| Revenue/Employee | 99,370.37 |
| Income Per Employee | -262,777.778 |
| Receivables Turnover | 2.236 |
| Total Asset Turnover | 0.122 |
PROF Liquidity
| Current Ratio | 12.525 |
| Quick Ratio | 11.169 |
| Cash Ratio | 9.831 |
PROF Profitability
| Gross Margin | 70.773 |
| Operating Margin | -256.268 |
| Pretax Margin | -262.877 |
| Net Margin | -264.443 |
| Return on Assets | -32.165 |
| Return on Equity | -67.115 |
| Return on Total Capital | -59.835 |
| Return on Invested Capital | -63.31 |
PROF Capital Structure
| Total Debt to Total Equity | 7.093 |
| Total Debt to Total Capital | 6.623 |
| Total Debt to Total Assets | 3.345 |
| Long-Term Debt to Equity | 6.772 |
| Long-Term Debt to Total Capital | 6.324 |